JPMorgan raised the firm’s price target on Intra-Cellular to $81 from $79 and keeps an Overweight rating on the shares. The higher target reflects the company’s “healthy” Q2 results and new fiscal 2024 Caplyta guidance, the analyst tells investors in a research note. The firm sees Intra-Cellular in a strong position to drive another inflection in Caplyta revenue with a new indication and sees the company’s profile as strategically attractive.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
- Intra-Cellular price target raised to $130 from $120 at Cantor Fitzgerald
- Intra-Cellular price target lowered to $74 from $77 at Goldman Sachs
- Intra-Cellular Therapies Welcomes New CFO Sanjeev Narula
- Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer